Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Risk Prediction Scores for Cardiotoxicity in Cancer Patients Treated With Cardiotoxic Anticancer Therapies in Europe (EUCARTOXSCORES)

20 juli 2026 uppdaterad av: University Hospital, Caen

Cancer management has undergone major advances over the past 30 years. Several anticancer therapies are now highly effective, allowing many cancers to become chronic diseases through sequential lines of treatment. However, these therapies may be associated with severe cardiovascular adverse events.

It is therefore essential to better understand the factors that determine, for a given patient and a given anticancer therapy, the occurrence of cardiovascular toxicity, and ideally to predict which patients are at highest risk.

The 2022 ESC Cardio-Oncology Guidelines strongly recommend risk stratification prior to the initiation of cardiotoxic anticancer therapies. Current recommendations suggest the use of risk scores known as "HFA-ICOS" scores. However:

Not all cardiotoxic anticancer therapies currently have an associated risk score; Existing scores are derived from small retrospective or prospective cohorts (typically fewer than 100 patients), and most have not undergone rigorous validation, leaving considerable room for improvement.

The EU-CARTOX-SCORES protocol aims to develop new prediction scores for cardiotoxicity occurring within the first year after initiation of cardiotoxic anticancer therapies. This protocol is innovative through the integration of artificial intelligence and/or machine learning approaches alongside conventional statistical methods. These models will be interfaced with a dedicated cardio-oncology digital platform (CardioOncoPilot), currently being deployed across the European Union, ensuring standardized and high-quality data collection within routine clinical care.

This is a prospective, multicenter, observational study designed as a European cardio-oncology registry, involving all European cardiologists using the platform in routine practice. The inclusion period will last 3 years, with a 12-month follow-up for each patient. At the time of data extraction, all available cases recorded in the CardioOncoPilot platform will be analyzed.

Overall, it is anticipated that between 1,000 and 5,000 patients across Europe will be included by the end of 2027. These patients will be managed in cardio-oncology clinics as part of routine care during treatment with cardiotoxic anticancer therapies, with follow-up conducted at the same center throughout the study.

The primary endpoint will be the occurrence of cardiotoxicity as defined by the 2022 ESC Guidelines. Additionally, the performance of newly developed prediction models will be compared with existing HFA-ICOS risk scores (when available) in the same patient population.

Patients will be followed according to routine clinical practice and in accordance with the 2022 ESC Cardio-Oncology Guidelines, which recommend both a baseline pre-treatment assessment and a follow-up evaluation at 1 year, regardless of the type of cardiotoxic therapy.

Patient management will not be modified by the study. This research will consist solely of secondary use of data collected during routine care.

Investigators anticipate that this study will significantly improve prognostic risk stratification tools in patients treated with cardiotoxic anticancer therapies, thereby enhancing identification of those at highest risk of clinically relevant cardiovascular adverse events during follow-up.

This project will be conducted in collaboration with the ESC Council of Cardio-Oncology, ensuring optimal dissemination through appropriate scientific channels. The developed scores will be shared with the scientific community, particularly the European Society of Cardiology (ESC), with the aim of informing future guideline updates.

Studieöversikt

Studietyp

Observationell

Inskrivning (Beräknad)

10000

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Testmetod

Icke-sannolikhetsprov

Studera befolkning

All consecutive patients seen in a cardio-oncology outpatient clinic at one of the participating centers during the inclusion period (June 2026 to December 2029) will be eligible for inclusion in the study.

Beskrivning

Inclusion Criteria:

  • Age ≥ 18 years
  • Diagnosis of cancer
  • Planned cardio-oncology follow-up as part of pre-treatment assessment prior to cardiotoxic anticancer therapy, as defined in the 2022 ESC Cardio-Oncology Guidelines

Exclusion Criteria:

  • Patients for whom 12-month follow-up is planned to be conducted outside the center that performed the baseline pre-treatment evaluation

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Cancer patients experiencing cardiovascular diseases
All consecutive patients seen in a cardio-oncology outpatient clinic at one of the participating centers during the inclusion period will be eligible for inclusion in the study and will be extracted from the COPilot tool
Cancer patients in which an anticancer drug is planned after the baseline cardio-oncological evaluation

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Occurrence of cardiotoxicity at 1-year follow-up, as defined by the 2022 ESC Guidelines.
Tidsram: from the baseline cardio-oncological evaluation and up to 1 year
from the baseline cardio-oncological evaluation and up to 1 year

Sekundära resultatmått

Resultatmått
Tidsram
Identification of baseline parameters obtained during the pre-treatment assessment (clinical, biological, ECG, or echocardiographic) associated with the occurrence of cardiotoxicity at 1 year, as defined by the 2022 ESC Guidelines.
Tidsram: from the baseline cardio-oncological evaluation and up to 1 year
from the baseline cardio-oncological evaluation and up to 1 year
Comparison of the performance of newly developed prediction scores with existing risk stratification scores (HFA-ICOS scores proposed in the 2022 ESC Guidelines), for each anticancer drug with an available HFA-ICOS score.
Tidsram: from the baseline cardio-oncological evaluation and up to 1 year
from the baseline cardio-oncological evaluation and up to 1 year

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

22 juni 2026

Primärt slutförande (Beräknad)

31 december 2029

Avslutad studie (Beräknad)

31 december 2030

Studieregistreringsdatum

Först inskickad

27 maj 2026

Först inskickad som uppfyllde QC-kriterierna

27 maj 2026

Första postat (Faktisk)

2 juni 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

22 juli 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

20 juli 2026

Senast verifierad

1 maj 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera